A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection

BMC Psychiatry

Shufang Wang¹  Michael G Case¹  David P McDonnell¹  Holland C Detke¹  Susan Atkins¹ 

[1] Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA

关键词: Pamoate;    Injection site reactions;    Adverse events;    Schizophrenia;    Olanzapine long-acting injection;   

Others  :  1123840
DOI  :  10.1186/1471-244X-14-7

 received in 2013-03-29, accepted in 2014-01-09,  发布年份 2014

【 摘 要 】

Background

Depot antipsychotic injections are an important tool for the management of patients with schizophrenia who have difficulty with adherence to oral medication. However, pain and discomfort at the injection site can be a potential impediment to the use of these long-acting formulations. We report here the results of a pooled analysis of injection site-related adverse events (AEs) collected during treatment with the olanzapine long-acting injection (olanzapine LAI).

Methods

Unsolicited injection site-related AEs were pooled from 7 olanzapine LAI clinical trials conducted in patients between March 2001 and December 2010. All patients had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia or schizoaffective disorder and were between the ages of 18 and 75. Doses ranged from 45 to 405 mg olanzapine LAI, and injection intervals were 2, 3, or 4 weeks. Events were evaluated for severity, timing, possible risk factors, and outcome. A criterion of p < .05 for statistical significance was used for all tests.

Results

A total of 1752 patients received at least 1 olanzapine LAI injection. Of these, 92 patients (5.3%) reported at least 1 injection site-related AE, with “pain” being the most common type (2.9%). Most events were mild (81.4%) and the median duration was 3 days. Four patients (0.2%) discontinued due to injection site-related AEs. Dose volume and body mass index did not appear to affect the probability of injection site-related AEs. However, patients who experienced a post-injection delirium/sedation syndrome event (n = 37) were more likely to have or have had an injection site-related AE at some time during the study. Incidence of injection site-related AEs appeared to decrease over time. In 94.2% of the injection site-related AEs, no specific treatment or concomitant medication was reported; in 9 cases, patients received pharmacologic treatment for reaction, mass, abscess, rash, or pain.

Conclusions

Injection site-related AEs with olanzapine LAI were generally mild. The incidence and nature of these injection site-related AEs were generally similar to those occurring during treatment with other injectable antipsychotics.

Trial registration

ClinicalTrials.gov ID; URL: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489.

【 授权许可】

   
2014 Atkins et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Schooler NR: Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003, 64(Suppl 16):14-17.
• [2]Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O: Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003, 64:1250-1257.
• [3]Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G: Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001, 62:855-859.
• [4]Hamann GL, Egan TM, Wells BG, Grimmig JE: Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 1990, 51:502-504.
• [5]Jones JC, Day JC, Taylor JR, Thomas CS: Investigation of depot neuroleptic injection site reactions. Psychiatr Bull 1998, 22:605-607.
• [6]Lindenmayer JP, Jarboe K, Bossie CA, Zhu Y, Mehnert A, Lasser R: Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005, 20:213-221.
• [7]Quiroz JA, Rusch S, Thyssen A, Palumbo JM, Kushner S: Deltoid injections of risperidone long-acting injectable in patients with schizophrenia. Innov Clin Neurosci 2011, 8:20-28.
• [8]Citrome L: Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010, 64:216-239.
• [9]Eli Lilly and Company: Zyprexa [package insert]. 2011.
• [10]Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D: Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010, 167:181-189.
• [11]Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D: An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008, 69:790-799.
• [12]McDonnell DP, Andersen SW, Detke HC, Zhao F, Watson SB: Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Insights: Psychiat 2011, 3:37-47.
• [13]Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiat 2010, 10:43. BioMed Central Full Text
• [14]Mamo D, Kapur S, Keshavan M, Laruelle M, Taylor CC, Kothare PA, Barsoum P, McDonnell D: D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008, 33:298-304.
• [15]McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, Sanchez-Felix MV, Sorsaburu S, Mitchell MI: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiat 2010, 10:45. BioMed Central Full Text
• [16]Canas F, Moller HJ: Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. Expert Opin Drug Saf 2010, 9:683-697.
• [17]Rodger MA, King L: Drawing up and administering intramuscular injections: a review of the literature. J Adv Nurs 2000, 31:574-582.
• [18]Workman B: Safe injection techniques. Nurs Stand 1999, 13:47-53.
• [19]Nicoll LH, Hesby A: Intramuscular injection: an integrative research review and guideline for evidence-based practice. Appl Nurs Res 2002, 15:149-162.